GM-CSF, carboplatin, doxorubicin: a phase I study

Elizabeth A. Poplin, David S. Alberts, John J. Rinehart, Harriet O. Smith, James A. Neidhart, Evan M. Hersh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Dose intensification has the potential to increase the response frequency of chemosensitive tumors to chemotherapy. G-CSF and GM-CSF offer the possibility of dose-intensifying chemotherapy without prohibitive myelosuppression. A phase I study was undertaken to identify the maximum tolerated dose (MTD) of carboplatin that could be administered with a fixed dose of doxorubicin, 60 mg/m2, administered every 28 days. Further escalation of the carboplatin dose was then attempted, with the concomitant addition of GM-CSF 10 mg/kg per day on days 1-21. We had 21 patients, 13 with prior therapy, who were eligible. In all, 60 courses of therapy were delivered, all with doxorubicin and with carboplatin doses of 250 mg/m2, 325 mg/m2 and 400 mg/m2. At carboplatin 400 mg/m2 and doxorubicin 60 mg/m2, thrombocytopenia was dose limiting. The addition of GM-CSF did not allow further escalation. Of the 6 patients treated with carboplatin 400 mg/m2, doxorubicin 60 mg/m2, and GM-CSF, grade 4 granulocytopenia and thrombocytopenia were seen in 4 and 5 patients, respectively. The severity of thrombocytopenia was related to the calculated carboplatin AUC and also to baseline platelet count and prior therapy. In addition, the interaction of GM-CSF and chemotherapy, especially carboplatin-based, may be more complex than originally anticipated.

Original languageEnglish (US)
Pages (from-to)340-346
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume33
Issue number4
DOIs
StatePublished - Jul 1994
Externally publishedYes

Fingerprint

Carboplatin
Granulocyte-Macrophage Colony-Stimulating Factor
Doxorubicin
Chemotherapy
Drug Therapy
Thrombocytopenia
Agranulocytosis
Maximum Tolerated Dose
Granulocyte Colony-Stimulating Factor
Platelets
Platelet Count
Area Under Curve
Frequency response
Tumors
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Poplin, E. A., Alberts, D. S., Rinehart, J. J., Smith, H. O., Neidhart, J. A., & Hersh, E. M. (1994). GM-CSF, carboplatin, doxorubicin: a phase I study. Cancer Chemotherapy and Pharmacology, 33(4), 340-346. https://doi.org/10.1007/BF00685910

GM-CSF, carboplatin, doxorubicin : a phase I study. / Poplin, Elizabeth A.; Alberts, David S.; Rinehart, John J.; Smith, Harriet O.; Neidhart, James A.; Hersh, Evan M.

In: Cancer Chemotherapy and Pharmacology, Vol. 33, No. 4, 07.1994, p. 340-346.

Research output: Contribution to journalArticle

Poplin, EA, Alberts, DS, Rinehart, JJ, Smith, HO, Neidhart, JA & Hersh, EM 1994, 'GM-CSF, carboplatin, doxorubicin: a phase I study', Cancer Chemotherapy and Pharmacology, vol. 33, no. 4, pp. 340-346. https://doi.org/10.1007/BF00685910
Poplin EA, Alberts DS, Rinehart JJ, Smith HO, Neidhart JA, Hersh EM. GM-CSF, carboplatin, doxorubicin: a phase I study. Cancer Chemotherapy and Pharmacology. 1994 Jul;33(4):340-346. https://doi.org/10.1007/BF00685910
Poplin, Elizabeth A. ; Alberts, David S. ; Rinehart, John J. ; Smith, Harriet O. ; Neidhart, James A. ; Hersh, Evan M. / GM-CSF, carboplatin, doxorubicin : a phase I study. In: Cancer Chemotherapy and Pharmacology. 1994 ; Vol. 33, No. 4. pp. 340-346.
@article{37231eb3931542079f8dfb1e1a0101ef,
title = "GM-CSF, carboplatin, doxorubicin: a phase I study",
abstract = "Dose intensification has the potential to increase the response frequency of chemosensitive tumors to chemotherapy. G-CSF and GM-CSF offer the possibility of dose-intensifying chemotherapy without prohibitive myelosuppression. A phase I study was undertaken to identify the maximum tolerated dose (MTD) of carboplatin that could be administered with a fixed dose of doxorubicin, 60 mg/m2, administered every 28 days. Further escalation of the carboplatin dose was then attempted, with the concomitant addition of GM-CSF 10 mg/kg per day on days 1-21. We had 21 patients, 13 with prior therapy, who were eligible. In all, 60 courses of therapy were delivered, all with doxorubicin and with carboplatin doses of 250 mg/m2, 325 mg/m2 and 400 mg/m2. At carboplatin 400 mg/m2 and doxorubicin 60 mg/m2, thrombocytopenia was dose limiting. The addition of GM-CSF did not allow further escalation. Of the 6 patients treated with carboplatin 400 mg/m2, doxorubicin 60 mg/m2, and GM-CSF, grade 4 granulocytopenia and thrombocytopenia were seen in 4 and 5 patients, respectively. The severity of thrombocytopenia was related to the calculated carboplatin AUC and also to baseline platelet count and prior therapy. In addition, the interaction of GM-CSF and chemotherapy, especially carboplatin-based, may be more complex than originally anticipated.",
author = "Poplin, {Elizabeth A.} and Alberts, {David S.} and Rinehart, {John J.} and Smith, {Harriet O.} and Neidhart, {James A.} and Hersh, {Evan M.}",
year = "1994",
month = "7",
doi = "10.1007/BF00685910",
language = "English (US)",
volume = "33",
pages = "340--346",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - GM-CSF, carboplatin, doxorubicin

T2 - a phase I study

AU - Poplin, Elizabeth A.

AU - Alberts, David S.

AU - Rinehart, John J.

AU - Smith, Harriet O.

AU - Neidhart, James A.

AU - Hersh, Evan M.

PY - 1994/7

Y1 - 1994/7

N2 - Dose intensification has the potential to increase the response frequency of chemosensitive tumors to chemotherapy. G-CSF and GM-CSF offer the possibility of dose-intensifying chemotherapy without prohibitive myelosuppression. A phase I study was undertaken to identify the maximum tolerated dose (MTD) of carboplatin that could be administered with a fixed dose of doxorubicin, 60 mg/m2, administered every 28 days. Further escalation of the carboplatin dose was then attempted, with the concomitant addition of GM-CSF 10 mg/kg per day on days 1-21. We had 21 patients, 13 with prior therapy, who were eligible. In all, 60 courses of therapy were delivered, all with doxorubicin and with carboplatin doses of 250 mg/m2, 325 mg/m2 and 400 mg/m2. At carboplatin 400 mg/m2 and doxorubicin 60 mg/m2, thrombocytopenia was dose limiting. The addition of GM-CSF did not allow further escalation. Of the 6 patients treated with carboplatin 400 mg/m2, doxorubicin 60 mg/m2, and GM-CSF, grade 4 granulocytopenia and thrombocytopenia were seen in 4 and 5 patients, respectively. The severity of thrombocytopenia was related to the calculated carboplatin AUC and also to baseline platelet count and prior therapy. In addition, the interaction of GM-CSF and chemotherapy, especially carboplatin-based, may be more complex than originally anticipated.

AB - Dose intensification has the potential to increase the response frequency of chemosensitive tumors to chemotherapy. G-CSF and GM-CSF offer the possibility of dose-intensifying chemotherapy without prohibitive myelosuppression. A phase I study was undertaken to identify the maximum tolerated dose (MTD) of carboplatin that could be administered with a fixed dose of doxorubicin, 60 mg/m2, administered every 28 days. Further escalation of the carboplatin dose was then attempted, with the concomitant addition of GM-CSF 10 mg/kg per day on days 1-21. We had 21 patients, 13 with prior therapy, who were eligible. In all, 60 courses of therapy were delivered, all with doxorubicin and with carboplatin doses of 250 mg/m2, 325 mg/m2 and 400 mg/m2. At carboplatin 400 mg/m2 and doxorubicin 60 mg/m2, thrombocytopenia was dose limiting. The addition of GM-CSF did not allow further escalation. Of the 6 patients treated with carboplatin 400 mg/m2, doxorubicin 60 mg/m2, and GM-CSF, grade 4 granulocytopenia and thrombocytopenia were seen in 4 and 5 patients, respectively. The severity of thrombocytopenia was related to the calculated carboplatin AUC and also to baseline platelet count and prior therapy. In addition, the interaction of GM-CSF and chemotherapy, especially carboplatin-based, may be more complex than originally anticipated.

UR - http://www.scopus.com/inward/record.url?scp=0027972626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027972626&partnerID=8YFLogxK

U2 - 10.1007/BF00685910

DO - 10.1007/BF00685910

M3 - Article

C2 - 8281628

AN - SCOPUS:0027972626

VL - 33

SP - 340

EP - 346

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -